Clinical

Christina Poh examined the highly individualized nature of the rituximab versus obinutuzumab decision in follicular lymphoma, framing it as a patient-specific assessment that must weigh efficacy advantages against a meaningfully higher tolerability burden that may not be appropriate for all patients.

Christina Poh reviewed the inMIND safety data, noting that the addition of tafasitamab to the lenalidomide and rituximab backbone produced a manageable safety profile that was generally consistent with the R² backbone alone with no major unexpected safety signals observed and overall good patient tolerability throughout the trial.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.

New study validates CVI Range-CR for measuring real-world vision in kids with cerebral visual impairment and tracking change over time.

Female newborns were more likely than males to miss vitamin K prophylaxis and hepatitis B birth doses, highlighting sex-based gaps in preventive care.

The FDA approved LEQEMBI IQLIK for once-weekly at-home subcutaneous initiation in early Alzheimer's disease based on IV and extension study data.

Veligrotug is a newly FDA-approved treatment that can target the proptosis associated with thyroid eye disease.

The 2026 State of Dry Eye survey links DED treatment to improved emotional well-being and quality of life amid delays in care and awareness gaps.

JAK inhibitors are reshaping alopecia areata care, while global registries aim to address long-term safety and effectiveness data gaps.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

New review finds psoriasis biologics generally preserve kidney function, with IL-17 inhibitors showing potential renal benefits.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

This episode, titled ‘Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies,’ featured panelists discussing the following critical questions

Learn how tumor and liquid biopsy biomarker tests are ordered, why results take weeks, and how insurance rules can delay cancer treatment.

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting disease-modifying potential.

A systematic review and meta-analysis, published in Frontiers in Nutrition, examines whether BMI predicts survival DLBCL, the most common subtype of non-Hodgkin lymphoma.

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Phase 3 TRANSCEND shows setmelanotide cuts BMI and hunger in acquired hypothalamic obesity, signaling a new targeted option after hypothalamic injury.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

This episode, titled 'Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression,' features Nadege Gunn, MD discussing the following critical questions: 1. How do you risk-stratify your patients, and what clinical or metabolic factors most reliably predict progression? 2. What does the literature tell us about the relationship between meaningful weight loss and fibrosis regression, and how does that inform your thinking about weight-loss therapy as a hepatic intervention?

In 'Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World,’ Nadege Gunn, MD delves into the following critical question: 1. There is growing interest in screening for MASH further upstream. What would a practical, scalable screening algorithm look like in your view, and what are the limitations of that approach?

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.